Prevalence of Hepatitis B Viral Infection and Associated Risk Factors among Residents of Goesa Community, Shendam LGC, Plateau State, Nigeria

Dombin Tyem Dinfa *

Fensyl MHP Consulting, 49 Kofo Abayomi Avenue, Apapa, Lagos, Nigeria.

Ehoche John Owunebe

Department of Chemistry, Eastern New Mexico University, 1500 South Avenue K, Portales, New Mexico, United States of America.

Rabo Clifford Naannoe

Jos University Teaching Hospital, Jos, Nigeria.

Oteh Peter Igoche

Ahmadu Ali Center for Public Health and Comparative Medicine, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Aim: To assess the prevalence of Hepatitis B viral infection and the associated risk factors among residents of Goesa community, Shendam Local Government Area, Plateau state, Nigeria.

Study Design: A prospective study conducted using non-probability sampling. Objective and subjective data on Hepatitis B viral infection and associated risk factors were collected using a pro-forma to obtain and record relevant information.

Place and Study Duration: Goesa community, Shendam Local Government Area, Plateau state, Nigeria; October 2022.

Methodology: A prospective study conducted using non-probability sampling to recruit 124 respondents that gave consent to be screened for Hepatitis B and participate in the study in October, 2022. A pro-forma was used to obtain information regarding demographics, risk factors associated with contracting Hepatitis B virus, previous Hepatitis B virus screening result and Hepatitis B virus vaccination history. These were determined by interviewing and testing each participant for Hepatitis B virus.

Results: A total of 124 study participants were screened for Hepatitis B with a mean age of 30 ±10.4 years. The study population comprised of equal numbers of males and females, 62 each. 41.9%, 51.6% and 6.5% had primary, secondary and tertiary level of education respectively and 78.2% were businessmen and women. Out of the 124 study participants, 14 tested positive to hepatitis B. About 2 (14.3%) of those who tested positive have a history of blood transfusion. Also, a statistically significant relationship exists between the level of education and participants’ history of Hepatitis B screening as revealed by the output of study analysis (p<0.05). The prevalence rate of Hepatitis B virus in Goesa community was 11.29%.

Conclusion: The prevalence rate of Hepatitis B infection among the study participants in Goesa community is 11.29%, and the most common risk factor associated with contracting this virus is a history of blood transfusion. Other risk behaviors practiced among the study population include body piercing (tattoo) and sharing of razor blades. Results of the study revealed that educated individuals in this community are more open to go for Hepatitis B screening than those that are uneducated.

Keywords: Hepatitis B, risk factors, screening, prevalence, associated


How to Cite

Dinfa , D. T., Owunebe , E. J., Naannoe , R. C., & Igoche , O. P. (2023). Prevalence of Hepatitis B Viral Infection and Associated Risk Factors among Residents of Goesa Community, Shendam LGC, Plateau State, Nigeria. Asian Journal of Medical Principles and Clinical Practice, 6(2), 334–341. Retrieved from https://journalajmpcp.com/index.php/AJMPCP/article/view/196

Downloads

Download data is not yet available.

References

World Health Organization. Global health report 2017. World Health Organization; 2017.

Tarrault NA, Lok AS, McMahon BJ, Chang, KM, Hwang JP, Jonas MM, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD2018 hepatitis B guidane. Hepatology. 2018;67(4):1560- 1599

El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7): 2557-2576.

Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. In Mayo clinic proceedings. August 2007;82(8):967-975. Elsevier.

Carroll L, Gellman MD, Turner JR.Prevalence. (eds), Encyclopedia of Behavioral Medicine; 2013.

Ajuwon BI, Yujuico I, Rosper K, Richardson A, Sheel M, Lidbury BA. Hepatitis B virus infection in Nigeria: a systemic review and meta-analysis of data published between 2010 and 2019. BMC infectious diseases. 2021;21(1):1- 15.

Itelima JU. Prevalence of Hepatitis B and C in Jos Plateau State, Nigeria. Journal of Antivirals and Antiretrovirals; 2017.

Fairly CK, Read TR. Vaccination against sexully transmitted infections. Current opinion on infectious diseases. 2012;25 (1):66-72.

Buddeberg F, Schimmer BB, Spahn DR. Transfusion-transmissible infections and transfusion-related immunomodulation. Best practice & research Clinical Anaesthesiology. 2008;22 (3), 503-517.

Shapiro CN. Epidemiology of hepatitis B. Pediatric infectiou disease journal. 1993;12 (5):433-437.

Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, An Y. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Archives of pediatrics & adolescent medicine. 2011;165 (9):837-846.

Banino F, Chiaberge E, Maran E, Piantino P. Serological markers of HBV infectivity. Ann Ist. Super. Sanita. 1987;24 (2):17-23.

Karayiannis P, Thomas HC, Mahy BW, Van Regenmortel MHV. Desk Encylopedia of Human and Medical Virology. Boston Academic Press. 2009;5:110- 115.

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, Md.). 2007;45(2): 507-539.

Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane database of systematic reviews. 2006;(2).

Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: A concise review of neonatal vertical transmission and antiviral prophylaxis. Annals of hepatology. 2014; 13(2):187-195.

Hyun MH, Lee YS, Kim JH, Je JH, Yoo HJ, Yeon JE, Byun KS. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Alimentary pharmacology & therapeutics. 2017;45 (12):1493-1505.

World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection: Mar-15. World Health Organization; 2015.

Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, Egwuenu-Oladejo A, Ajisegiri SW, Sha'aibu S, Musa BO, Gidado S, Nasidi A. Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey. Am J Trop Med Hyg. 2016 Oct 5;95(4):902-907.

DOI: 10.4269/ajtmh.15-0874.

Epub 2016 Aug 15.

PMID: 27527630;

PMCID: PMC5062798.

Chul S, Hyun MH, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of chronic hepatitis B virus infection in the United Stastes of America. Journal on Viral Hepatitis, 2016;15(1):12- 33.

Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Annals of hepatology. 2014; 13(2):187-195.

Mitchell AE, Colvin HM. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis b and C; 2010.

Tarrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Wong JB. Update on prevention, diagnosis, and treatment of Chronic hepatitis B: AASLD2018 hepatitis B guidane. Hepatology. 2018;67(4):1560- 1599